

New Drug Approvals

Generic Name (Trade Name) Company

September 28, 2015

Insulin degludec injection, insulin degludec/insulin aspart injection

Uses/Notes

[FDA has approved](#) insulin degludec injection under the trade name Tresiba and insulin degludec/insulin aspart injection under the trade name Ryzodeg 70/30 to improve blood glucose control in adults with diabetes.

Tresiba is a long-acting insulin analog indicated to improve glycemic control in adults with type 1 and 2 diabetes. Dosing should be individualized according to the patient's needs. Tresiba is administered subcutaneously once daily at any time of day.

Efficacy and safety of Tresiba used in combination with mealtime insulin for the treatment of patients with type 1 diabetes were evaluated in two 26-week and one 52-week active-controlled clinical trials involving 1,102 participants exposed to Tresiba.

Efficacy and safety of Tresiba used in combination with mealtime insulin or used as add-on to common background oral antidiabetic drugs for the treatment of patients with type 2 diabetes were evaluated in four 26-week and two 52-week active-controlled clinical trials involving 2,702 participants exposed to Tresiba.

In participants with type 1 and 2 diabetes who had inadequate blood sugar control at trial entry, treatment with Tresiba provided reductions in glycosylated hemoglobin (A1C) in line with reductions achieved with other, previously approved long-acting insulin.

Ryzodeg 70/30 is a mixture of insulin degludec, a long-acting insulin analog, and insulin aspart, a rapid-acting human insulin analog.

Efficacy and safety of Ryzodeg 70/30 used in combination with mealtime insulin for the treatment of patients with type 1 diabetes were evaluated in one 26-week active controlled clinical trial involving 362 participants exposed to Ryzodeg 70/30.

Efficacy and safety of Ryzodeg 70/30 administered once or twice daily for the treatment of patients with type 2 diabetes were evaluated in four active-controlled

(Tresiba, Ryzodeg 70/30—Novo Nordisk)

FDA approves two new drug treatments for diabetes

26-week clinical trials involving 998 participants exposed to Ryzodeg 70/30.

In participants with type 1 and 2 diabetes who had inadequate blood glucose control at trial entry, treatment with Ryzodeg 70/30 provided reductions in A1C equivalent to reductions achieved with other, previously approved long-acting or pre-mixed insulin.

Tresiba and Ryzodeg should not be used in those who have diabetic ketoacidosis. Patients or caregivers should monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Tresiba and Ryzodeg may cause hypoglycemia, which can be life-threatening. Patients should be monitored more closely with changes to insulin dosage, coadministration of other glucose-lowering medications, meal pattern, physical activity, and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness.

Severe, life-threatening, generalized allergy, including anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, and shock may occur with any insulin.

The most common adverse reactions associated with Tresiba and Ryzodeg in clinical trials were hypoglycemia, allergic reactions, injection site reactions, pitting at the injection site (lipodystrophy), itching, rash, edema, and weight gain.

Source URL:

<http://www.aphanet.org/new-drug-approvals/fda-approves-two-new-drug-treatments-diabetes>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.